Two doses of a simple tuberculosis vaccine after surgery support the immune system in fighting cancer cells and could significantly improve treatment outcomes for the most common form of bladder cancer, according to a pilot study involving 40 patients. Initial results of the RUTIVAC-1 study were presented at EAU25.
Autoren
- Birke Dikken
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
You May Also Like
- Update 2025
Hypercholesterolemia
- GPP: from molecular principles to targeted therapy
Therapeutic rationale for targeted IL-36 receptor inhibition
- HFpEF 2025
Precision medicine and phenotypes
- Myelofibrosis
New treatment options for myelofibrosis patients with a high risk of anemia?
- Chronic insomnia in adults: Guideline recommendations
CBT-i as first choice – pharmacotherapy as secondary intervention
- Pulmonary hypertension
PH and lung diseases
- COPD therapy
Drug therapy – Update 2025
- IBDmatters - Synergy effects for IBD pathways